These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
102 related articles for article (PubMed ID: 20008750)
1. ACP Journal Club. Continuous androgen-deprivation therapy increased risk for diabetes and fragility fractures in older men with prostate cancer. Hajdenberg J Ann Intern Med; 2009 Dec; 151(12):JC6-14. PubMed ID: 20008750 [No Abstract] [Full Text] [Related]
2. Fracture types and risk factors in men with prostate cancer on androgen deprivation therapy: a matched cohort study of 19,079 men. Alibhai SM; Duong-Hua M; Cheung AM; Sutradhar R; Warde P; Fleshner NE; Paszat L J Urol; 2010 Sep; 184(3):918-23. PubMed ID: 20643458 [TBL] [Abstract][Full Text] [Related]
3. ACP Journal Club. Intermittent and continuous androgen deprivation did not differ for mortality after radiotherapy for prostate cancer. Stockler MR Ann Intern Med; 2013 Jan; 158(2):JC9. PubMed ID: 23318343 [No Abstract] [Full Text] [Related]
4. Toremifene to reduce fracture risk in men receiving androgen deprivation therapy for prostate cancer. Smith MR; Morton RA; Barnette KG; Sieber PR; Malkowicz SB; Rodriguez D; Hancock ML; Steiner MS J Urol; 2013 Jan; 189(1 Suppl):S45-50. PubMed ID: 23234631 [TBL] [Abstract][Full Text] [Related]
5. ACP Journal Club. Review: Androgen deprivation therapy does not increase CV mortality in prostate cancer. Canfield SE; Dahm P Ann Intern Med; 2012 Apr; 156(8):JC4-04, JC4-05. PubMed ID: 22508744 [No Abstract] [Full Text] [Related]
6. ACP Journal Club. Radiation plus androgen deprivation therapy reduced mortality in locally advanced prostate cancer. Canfield SE; Dahm P Ann Intern Med; 2012 Apr; 156(8):JC4-05, JC4-04. PubMed ID: 22508745 [No Abstract] [Full Text] [Related]
7. Increased risk of metabolic syndrome, diabetes mellitus, and cardiovascular disease in men receiving androgen deprivation therapy for prostate cancer. Kintzel PE; Chase SL; Schultz LM; O'Rourke TJ Pharmacotherapy; 2008 Dec; 28(12):1511-22. PubMed ID: 19025432 [TBL] [Abstract][Full Text] [Related]
8. Impact of androgen deprivation therapy on weight gain differs by age in men with nonmetastatic prostate cancer. Timilshina N; Breunis H; Alibhai SM J Urol; 2012 Dec; 188(6):2183-8. PubMed ID: 23083859 [TBL] [Abstract][Full Text] [Related]
9. The role of bisphosphonates in men with prostate cancer receiving androgen deprivation therapy. Smith MR Oncology (Williston Park); 2004 May; 18(5 Suppl 3):21-5. PubMed ID: 15202584 [TBL] [Abstract][Full Text] [Related]
10. Health care cost associated with prostate cancer, androgen deprivation therapy and bone complications. Krupski TL; Foley KA; Baser O; Long S; Macarios D; Litwin MS J Urol; 2007 Oct; 178(4 Pt 1):1423-8. PubMed ID: 17706711 [TBL] [Abstract][Full Text] [Related]
11. Managing bone loss in men with locally advanced prostate cancer receiving androgen deprivation therapy. Israeli RS; Ryan CW; Jung LL J Urol; 2008 Feb; 179(2):414-23. PubMed ID: 18076933 [TBL] [Abstract][Full Text] [Related]
12. Bone health in men receiving androgen deprivation therapy for prostate cancer. Eastham JA J Urol; 2007 Jan; 177(1):17-24. PubMed ID: 17161994 [TBL] [Abstract][Full Text] [Related]
13. Finnish multicenter study comparing intermittent to continuous androgen deprivation for advanced prostate cancer: interim analysis of prognostic markers affecting initial response to androgen deprivation. Salonen AJ; Viitanen J; Lundstedt S; Ala-Opas M; Taari K; Tammela TL; J Urol; 2008 Sep; 180(3):915-9; discussion 919-20. PubMed ID: 18635219 [TBL] [Abstract][Full Text] [Related]
14. ACP Journal Club. Vitamin E supplementation increased risk for prostate cancer in healthy men at a median of 7 years. Hoffman RM Ann Intern Med; 2012 Feb; 156(4):JC2-03. PubMed ID: 22351729 [No Abstract] [Full Text] [Related]
15. Outcome predictors of radical prostatectomy followed by adjuvant androgen deprivation in patients with clinical high risk prostate cancer and pT3 surgical margin positive disease. Spahn M; Briganti A; Capitanio U; Kneitz B; Gontero P; Karnes JR; Schubert M; Montorsi F; Scholz CJ; Bader P; van Poppel H; Joniau S; J Urol; 2012 Jul; 188(1):84-90. PubMed ID: 22578727 [TBL] [Abstract][Full Text] [Related]
16. Zoledronic acid initiated during the first year of androgen deprivation therapy increases bone mineral density in patients with prostate cancer. Ryan CW; Huo D; Demers LM; Beer TM; Lacerna LV J Urol; 2006 Sep; 176(3):972-8; discussion 978. PubMed ID: 16890673 [TBL] [Abstract][Full Text] [Related]
17. Treatment of patients with high risk localized prostate cancer: results from cancer of the prostate strategic urological research endeavor (CaPSURE). Meng MV; Elkin EP; Latini DM; Duchane J; Carroll PR J Urol; 2005 May; 173(5):1557-61. PubMed ID: 15821485 [TBL] [Abstract][Full Text] [Related]
18. Osteoporosis in men treated with androgen deprivation therapy for prostate cancer. Ross RW; Small EJ J Urol; 2002 May; 167(5):1952-6. PubMed ID: 11956415 [TBL] [Abstract][Full Text] [Related]
19. Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapies. Diamond TH; Higano CS; Smith MR; Guise TA; Singer FR Cancer; 2004 Mar; 100(5):892-9. PubMed ID: 14983482 [TBL] [Abstract][Full Text] [Related]
20. Association between androgen-deprivation therapy and incidence of diabetes among males with prostate cancer. Lage MJ; Barber BL; Markus RA Urology; 2007 Dec; 70(6):1104-8. PubMed ID: 18158027 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]